Tag: MONOGRAPH

  • CDP-Choline (Citicoline)

    Cholinergic precursor / nucleotide

    Cytidine 5′-diphosphocholine, an endogenous nucleotide intermediate in phosphatidylcholine synthesis with neuroprotective and cognitive enhancement applications.

    Abstract

    Citicoline (cytidine 5′-diphosphocholine, CDP-Choline; CAS 987-78-0; molecular formula C14H26N4O11P2; molecular weight 488.32) is an endogenous nucleotide intermediate in the Kennedy pathway for phosphatidylcholine biosynthesis. Exogenous citicoline is hydrolyzed in the gut to cytidine and choline, which are absorbed independently and reassembled centrally as needed. The bioavailability profile differs from alpha-GPC: citicoline does not cross the blood-brain barrier intact at therapeutic concentrations; the elevation in central choline derives from increased availability of the precursor pools. The compound is approved as a medicine in many countries (Italy, Spain, Japan, Mexico, much of Latin America) for ischemic stroke, traumatic brain injury, and chronic cerebrovascular disease. Large randomized trials (ICTUS, COBRIT) have produced mixed results; meta-analysis suggests modest benefit in acute stroke recovery and chronic cognitive impairment with effect sizes in the 0.2 to 0.4 range. The compound is sold as a dietary supplement in the United States. Pharmacokinetics: plasma half-life of cytidine and choline components is several hours after dissociation; the CDP-Choline structure itself is not detectable in serum after oral administration. Excellent safety profile with rare serious adverse events.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • F-Phenibut (Fluorophenibut)

    GABA-B agonist / fluoro-phenibut

    A 4-fluoro-substituted phenibut analog with higher GABA-B affinity and lower dose requirement; sold as a research chemical with elevated dependence concerns.

    Abstract

    F-Phenibut (4-amino-3-(4-fluorophenyl)butanoic acid) is a fluorinated analog of phenibut with the addition of a para-fluoro substituent on the phenyl ring. The compound is not approved in any jurisdiction and is sold as a research chemical. Mechanism parallels phenibut (GABA-B agonist) with the affinity increase. Dependence liability is at least as substantial as phenibut and may be greater on a dose-equivalent basis. Pharmacokinetics are not formally characterized in humans; rodent half-life is similar to phenibut. F-phenibut should be regarded as a higher-potency phenibut analog with all the dependence concerns of phenibut amplified by potency.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Melanotan II

    Cyclic alpha-MSH analog

    A cyclic alpha-MSH analog with both skin pigmentation and sexual response effects, sold as a research chemical with significant safety concerns.

    Abstract

    Melanotan II (MT-II; CAS 121062-08-6; molecular formula C50H69N15O9; molecular weight 1024.18) is a cyclic heptapeptide alpha-MSH analog developed at the University of Arizona in parallel with Melanotan I. The compound shows higher receptor affinity than the linear Melanotan I but with non-selective melanocortin receptor activity (MC1, MC3, MC4, MC5). The clinical effect profile combines the skin pigmentation of MC1 activation with the sexual response effects of MC4 activation; this dual activity led to development of the more selective bremelanotide for sexual function applications and sustained pigmentation via Melanotan I. Melanotan II is not approved by any regulatory authority and is sold as a research chemical with significant safety concerns: the non-selective receptor activity produces reliable adverse events including nausea, flushing, blood pressure elevation, and concerning case reports of melanocyte dysplasia and atypical mole development. The compound should be regarded as substantially more hazardous than the more selective marketed melanocortin agonists.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Eleuthero (Eleutherococcus senticosus)

    Siberian ginseng adaptogen

    A Siberian Eleutherococcus root extract historically classified as ‘ginseng’ but unrelated to Panax; characterized by eleutherosides with adaptogenic activity.

    Abstract

    Eleuthero (Eleutherococcus senticosus, formerly called Siberian ginseng) is a shrub root used in Russian and Chinese traditional medicine for fatigue, stress tolerance, and immune support. The active constituents are eleutherosides A through G, glycoside compounds with diverse structures (some are syringaresinol diglucosides, others are sesamin glucosides). The compound is structurally and pharmacologically distinct from Panax ginseng despite the historical “ginseng” naming. Russian research from the 1960s-1980s established the compound as an adaptogen with modest effects on physical and mental performance. The Western clinical evidence base is limited.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Dulaglutide

    Weekly GLP-1 Fc fusion

    A GLP-1 analog fused to human IgG4 Fc for weekly dosing, FDA-approved as Trulicity for T2DM.

    Abstract

    Dulaglutide (Trulicity; CAS 923950-08-7; molecular weight ~63000) is an IgG4-Fc fusion protein containing two modified GLP-1(7-37) sequences. The Fc fusion provides extended half-life of approximately 5 days through neonatal Fc receptor recycling, supporting once-weekly subcutaneous dosing. The compound was developed by Eli Lilly and approved by the FDA in 2014 for T2DM. The cardiovascular outcomes program (REWIND) demonstrated MACE reduction in T2DM patients with cardiovascular risk factors.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Doxepin (Low-Dose)

    Tricyclic antidepressant / H1 antagonist

    Abstract

    At low doses, the compound shows selective H1 antihistamine activity; muscarinic, alpha-1 adrenergic, and serotonergic activities relevant at higher antidepressant doses are minimal. The H1-mediated sleep maintenance effect targets sleep continuity rather than sleep onset. Pharmacokinetics: plasma half-life 15 hours; CYP2D6 and CYP1A2 metabolism. Schedule status: prescription-only; not federally scheduled.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Kanna (Sceletium tortuosum)

    South African botanical / SSRI-like alkaloids

    A South African succulent containing mesembrine alkaloids with serotonin reuptake inhibition and PDE4 inhibition activities.

    Abstract

    Kanna (Sceletium tortuosum) is a succulent native to South Africa with traditional use for mood elevation and anxiety. Active constituents are mesembrine alkaloids (mesembrine, mesembrenone, mesembrenol). Pharmacology includes serotonin reuptake inhibition (mesembrine has SSRI-like activity) and phosphodiesterase 4 (PDE4) inhibition (mesembrenone), the latter providing anti-inflammatory and modest cognitive effects through cAMP elevation. The compound has been formulated as standardized extracts (Zembrin) and studied in small Phase 2 trials for anxiety with positive but modest results.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Milnacipran

    Serotonin-norepinephrine reuptake inhibitor

    An SNRI marketed in Europe and Japan for depression and FDA-approved for fibromyalgia, with balanced SERT/NET inhibition.

    Abstract

    Milnacipran (Savella, Ixel; CAS 92623-85-3; molecular formula C15H22N2O; molecular weight 246.35) is a serotonin-norepinephrine reuptake inhibitor (SNRI) marketed in Europe, Japan, and Australia for major depressive disorder and FDA-approved in 2009 (Savella) for fibromyalgia. The compound has more balanced SERT and NET inhibition than venlafaxine or duloxetine (which are SERT-biased), with NET inhibition more prominent at lower doses.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Desvenlafaxine

    Active metabolite of venlafaxine (SNRI)

    The major active metabolite of venlafaxine; a pure SNRI marketed separately to bypass CYP2D6 polymorphism.

    Abstract

    Desvenlafaxine (4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol; CAS 93413-62-8; molecular formula C16H25NO2; molecular weight 263.38) is the O-desmethylated active metabolite of venlafaxine, marketed as Pristiq by Wyeth/Pfizer after FDA approval in 2008. The compound is a structurally similar SNRI to venlafaxine with comparable SERT (Ki approximately 40 nM) and NET (Ki approximately 558 nM) affinity but a more balanced ratio than the parent compound, producing meaningful NET inhibition at lower doses. The principal pharmacokinetic advantage is bypass of CYP2D6 metabolism: desvenlafaxine is conjugated and excreted directly without further hepatic transformation, producing flat steady-state concentrations across CYP2D6 phenotypes and minimal drug-drug interaction potential. Discontinuation syndrome is comparable to venlafaxine. Used as a reference SNRI compound when CYP2D6 variability is undesirable.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Tranylcypromine

    Irreversible non-selective MAO inhibitor (amphetamine-related)

    A non-hydrazine cyclopropylamine MAOI structurally related to amphetamine; rapid-onset compared to phenelzine.

    Abstract

    Tranylcypromine ((1S,2R)-2-phenylcyclopropan-1-amine; CAS 155-09-9; molecular formula C9H11N; molecular weight 133.19) is a non-hydrazine cyclopropylamine MAOI approved by the FDA in 1961 under the trade name Parnate. The cyclopropylamine scaffold is structurally related to amphetamine, producing weak monoamine release in addition to MAO inhibition; the result is faster antidepressant onset (1 to 2 weeks) than phenelzine (3 to 6 weeks) and a mildly activating subjective profile. Inhibition of both MAO-A and MAO-B is irreversible, with similar tyramine cheese-effect risk. Plasma half-life is 1.5 to 3.2 hours, but enzyme inhibition persists for 5 to 10 days. The (-)-trans isomer is the predominant active form; clinical preparations are racemic. Hepatic metabolism is minor; the compound is largely excreted unchanged. Approved for major depressive disorder; used in atypical and treatment-resistant depression. Used as a non-hydrazine MAOI reference compound and as a positive control in dopaminergic and norepinephrine release studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.